Stephen Davis sold $475k of ACAD
CEO at ACADIA PHARMACEUTICALS INC. 26,574 shares at an average of $17.87, traded Apr 8, 2024, filed Apr 9, 2024.
Score components
- +25RoleCEO
- +17Trade size$475k at market
- +5Share of holdings soldSold 16% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.2%, 3m -5.6%, 6m -20.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-010604, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 5, 2024 | MOption exercise Common Stock | +17,333 | - | - | 136,175 | Apr 9, 2024 |
| Apr 5, 2024 | MOption exercise Common Stock | +34,666 | - | - | 170,841 | Apr 9, 2024 |
| Apr 8, 2024 | SOpen-market sale Common Stock10b5-1 | -8,858 | $17.87 | $158k | 161,983 | Apr 9, 2024 |
| Apr 8, 2024 | SOpen-market sale Common Stock10b5-1 | -17,716 | $17.87 | $317k | 144,267 | Apr 9, 2024 |
| Apr 5, 2024 | MOption exercise Restricted Stock Unitsderivative | -17,333 | $0.00 | $0 | 34,667 | Apr 9, 2024 |
| Apr 5, 2024 | MOption exercise Restricted Stock Unitsderivative | -34,666 | $0.00 | $0 | 138,666 | Apr 9, 2024 |
Related signals
Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $587k 20,141 shares | -27% | |
| 15Weak | ACADIA PHARMACEUTICALS INC | Elizabeth H.Z. Thompson EVP, Head of Research & Dev | $433k 16,558 shares | -47% | |
| 19Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $298k 11,421 shares | -47% | |
| 30Weak | ACADsell ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $114k 5,401 shares | -18% | |
| 0Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $29k 1,332 shares | -4% | |
| 3Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $76k 3,506 shares | -5% | |
| 0Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $23k 1,030 shares | -4% | |
| 9Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $60k 2,709 shares | -4% | |
| 14Weak | ACADIA PHARMACEUTICALS INC | Jennifer J Rhodes EVP, CHIEF LEGAL OFFICER, SEC | $83k 3,844 shares | -25% | |
| 1Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $42k 1,942 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.